I. Core Definitions and Testing Objectives of the USP <701> Disintegration Regulations

1. Legal positioning and definition :

   • Disintegration is not the same as dissolution : Disintegration refers to the physical process by which a solid oral preparation breaks down into small particles or soft matter within a specified time limit under the influence of a specified liquid medium and mechanical motion.

   • Criteria for complete disintegration : At the end of the test, all residues remaining on the metal mesh, except for insoluble coating fragments or capsule shells, must be soft mass with no palpably firm core ; or the material must pass completely through the metal mesh with no residue remaining on the mesh.

2. Clinical and process significance :

   • As a key physical property indicator for release testing and in-process control (IPC) of oral solid dosage forms (tablets, capsules).

   • This ensures that the drug disintegrates within the target physiological time after entering the digestive tract, laying the foundation for the subsequent dissolution and absorption of the active pharmaceutical ingredient (API).

II. Instrument Mechanism and Key Physical Specifications

1. Standard Device A (Apparatus A, suitable for standard tablets and capsules) :

   • Suspended basket pipe fitting dimensions : 6 vertical transparent pipes, with a length of 77.5 ± 2.5 mm, an inner diameter of 21.5 ± 0.5 mm, and a wall thickness of approximately 2.0 mm.

   • Bottom metal mesh : woven stainless steel mesh with aperture specifications of 1.8 mm to 2.2 mm (wire diameter of approximately 0.57 to 0.66 mm, conforming to standard 10-mesh).

   • Mechanical motion parameters :

     • Rise and fall frequency : 29 to 32 times/minute (cycles/min) .

     • Stroke Length : 53 to 57 mm (nominal 55 ± 2 mm).

     • Immersion depth : At the highest point, the distance between the sieve and the liquid surface shall not be less than 15 mm ; at the lowest point, the distance between the sieve and the bottom of the beaker shall not be less than 25 mm .

   • Beaker and temperature control : The medium is contained in a 1 L flat-bottomed beaker and the water bath is precisely maintained at 37 ± 2 °C (except for special items).

2. Auxiliary baffle (flushed disc) specifications :

   • Usage restrictions : This may only be included when specifically noted for use in a particular drug heading (Monograph) .

   • Physical specifications : Thickness 9.5 ± 0.15 mm, outer diameter 20.7 ± 0.15 mm, specific gravity (density) between 1.18 and 1.20 g/cm³ .

   • The side is equipped with 4 symmetrical fluid guide channels to ensure vertical and smooth liquid flow and prevent light tablets from floating or adhering to the tube wall.

3. Device B (Apparatus B, for large-size dosage forms) :

   • Specifically designed for use with large tablets or capsules that are longer or have a larger diameter (usually greater than 18 mm).

   • The basket consists of three large-diameter vertical tubes (approximately 33.0 mm inner diameter), with the same stroke and frequency as device A.

III. Testing Procedures and Acceptance Criteria for Each Dosage Form

1. Uncoated Tablets :

   • First stage : Take 6 samples and place them in 6 tubes respectively. Within the specified time limit (pure water, 37 ± 2 °C) , all 6 samples must completely disintegrate .

   • Phase Two (Retest) : If one or two samples fail to completely disintegrate, an additional 12 samples are taken for retesting. Of the total 18 samples, at least 16 must completely disintegrate to be considered合格 (qualified/acceptable).

2. Plain Coated Tablets / Film-Coated Tablets :

   • The testing procedure is exactly the same as the 16/18 decision rule . A stopcock may be added if Monograph permits. The film-coated tablet time limit is usually 30 minutes, while sugar-coated tablets are usually allowed up to 60 minutes.

3. Delayed-Release / Enteric-Coated Tablets :

   • Acid Stage : The tablets are run in 0.1 N HCl for 1 hour (without a stopper). Judgment Criteria: No disintegration, cracking, or core softening is observed on the tablet's surface .

   • Buffer Stage : After removal, rinse gently with pure water and transfer to pH 6.8 phosphate buffer (37 ± 2 °C) for operation for the specified period. Judgment Criteria: According to the 16/18 judgment criteria, all samples must completely disintegrate .

4. Sublingual and buccal tablets :

   • According to the item, the test must be conducted within a specified very short time limit (usually a few minutes), and the use of a shield is strictly prohibited to simulate the state of micro-saliva immersion in the oral cavity.

5. Hard/Soft Gelatin Capsules :

   • The criteria for judgment are the same as for uncoated tablets. If the soft capsules float on water, a Monograph-approved hanging basket with a mesh can be used. If a small amount of the capsule shell remains undissolved but the contents have been completely released and there is no hard core, it is considered acceptable.

IV. Regulatory Coordination and Data Integrity (ICH & Data Integrity)

1. International Pharmacopoeia Harmonization (ICH Q4B Annex 5) :

   • USP <701>, European Pharmacopoeia EP <2.9.1> and Japanese Pharmacopoeia JP <6.09> have completed tripartite coordination, and the frequency of increase and decrease, stroke length, screen aperture and 16/18 judgment criteria are fully mutually recognized.

2. Instrument hardware and data integrity regulations require :

   • Hardware and software compliance : Fully compliant with FDA 21 CFR Part 11 and ALCOA+ data integrity standards.

   • Automated Endpoint Detection : Overcoming the subjective bias of traditional human vision, it uses metal contact short-circuit resistance or optical sensing to automatically and accurately record the second-level collapse point of each tablet as it penetrates the screen.

   • Audit Trail : An unalterable timestamp record that fully documents parameter values before and after modification, temperature logs for each well, seconds of sample disintegration, and user account.

   • User access control : It has three or more levels of independent passwords and permissions protection for administrators (Admin), technicians (Tech), and operators (Operator).

   • Validation documentation support : The manufacturer must provide complete DQ (Design Qualification), IQ (Installation Qualification), OQ (Operation Qualification), and PQ (Performance Qualification) standard validation documentation.

V. Qinwei Technology Perspective

In line with current cGMP and global regulatory reporting trends for oral solid dosage forms (OSDs), disintegration testing has evolved from simple visual timing to a key quality control indicator emphasizing "mechanical and physical validity" and "automated endpoint data integrity." Traditional visual methods often lead to OOS/OOT investigation disputes due to turbid media and subjective differences in operator judgment. Introducing automated disintegration testing systems compliant with USP <701> / EP <2.9.1> standards (such as models equipped with electric automatic lifting, online electronic probe terminal detection, independent water bath circulating temperature control, and 21 CFR Part 11 audit tracking) not only ensures the objective reproducibility of batch release testing but also significantly simplifies the validation audit process. Chinwei Technology is committed to introducing high-end solid dosage form physical testing systems compliant with International Pharmacopoeia standards, providing comprehensive professional technical services from instrument setup and mechanical parameter calibration to DQ/IQ/OQ/PQ validation documentation support.

VI. References and Sources

• USP <701> Disintegration — United States Pharmacopeia.

• USP <2040> Disintegration and Dissolution of Dietary Supplements — United States Pharmacopeia.

• EP <2.9.1> Disintegration of Tablets and Capsules — European Pharmacopoeia.

• JP <6.09> Disintegration Test — Japanese Pharmacopoeia.

• ICH Q4B Annex 5 — Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Disintegration Test General Chapter.

• US FDA 21 CFR Part 11 — Electronic Records; Electronic Signatures.

• Taiwan Pharmacopoeia 9th Ed. – General Examination Method: Disintegration Test.